Clinical Trials Logo

Atrial Fibrillation Rapid clinical trials

View clinical trials related to Atrial Fibrillation Rapid.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04849312 Not yet recruiting - Asthma Clinical Trials

Prediction of 30-Day Readmission Using Machine Learning

Start date: March 20, 2022
Phase:
Study type: Observational

This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict the likelihood of 30-day readmission throughout a patient's admission. This algorithm was then validated in a validation cohort.

NCT ID: NCT03715556 Not yet recruiting - Atrial Fibrillation Clinical Trials

Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response

FAARV
Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

Amiodarone is considered the medicine of choice in heart rate control in critically ill patients with atrial fibrillation with high ventricular response. However, a recent retrospective study showed a greater number of events in critical patients in whom there was an attempt to control versus in which there was no. Therefore, the prospective and randomized comparative use of amiodarone in this group of patients has not yet been described. The aim of this study was to evaluate the safety of the use of amiodarone (restricted group) versus placebo (liberal group) in heart rate control in atrial fibrillation with high ventricular response in patients with sepsis and vasopressor cardiovascular dysfunction. For this, a unicentric, randomized, blind and prospective study will be performed, in which the restrictive versus liberal strategy is performed in a comparative way. Hospital data (test results, medical evolutions complications) of patients will be analyzed to calculate safety and effectiveness. Expected results: The liberal strategy is superior to the restrictive strategy and causes fewer adverse events.